Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1282
- Registration Number
- NCT01606007
- Locations
- 🇺🇸
Willamette Valley Clinical Studies, Eugene, Oregon, United States
🇺🇸Pmg Research Of Knoxville, Knoxville, Tennessee, United States
🇺🇸Excel Clinical Research, Llc, Houston, Texas, United States
PK Study of Dapagliflozin in Pediatric Subjects With T2DM
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT01525238
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Lsuhsc-Shreveport, Shreveport, Louisiana, United States
🇺🇸Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 171
- Registration Number
- NCT01498185
- Locations
- 🇺🇸
La Biomed Research Inst. At Harbor Ucla Med Ctr., Torrance, California, United States
🇺🇸Va San Diego Healthcare System, San Diego, California, United States
🇺🇸Vince And Associates Clinical Research, Overland Park, Kansas, United States
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
- Conditions
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2019-10-29
- Target Recruit Count
- 18
- Registration Number
- NCT01439854
- Locations
- 🇺🇸
Diabetes Division, UTHSCSA, San Antonio, Texas, United States
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 311
- Registration Number
- NCT01392677
- Locations
- 🇪🇸
Research Site, Sta Coloma de Gramenet (BCN), Spain
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 728
- Registration Number
- NCT01294436
- Locations
- 🇯🇵
Research Site, Toyama, Japan
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 261
- Registration Number
- NCT01294423
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 375
- Registration Number
- NCT01257412
- Locations
- 🇮🇳
Research Site, Ghaziabad, Uttar Pradesh, India
Evaluation of Dapagliflozin Taken Twice-daily
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT01217892
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
- Conditions
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2245
- Registration Number
- NCT01195662
- Locations
- 🇺🇸
Abington Memorial Hos/Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States
🇺🇸The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States
🇺🇸Research Across America, Reading, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.